 RESEARCH TRIANGLE PARK, N.C., July 19, 2021 GLOBE NEWSWIRE -- G1 Therapeutics, Inc. Nasdaq: GTHX, a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation to COSELATM trilaciclib investigation for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer TNBC. COSELA is currently being evaluated in PRESERVE 2, a pivotal Phase 3, randomized, double-blind, placebo-controlled study NCT04799249 in patients receiving first- or second-line gemcitabine and carboplatin chemotherapy for TNBC. press release 